Skip to main content
Premium Trial:

Request an Annual Quote

Predicine, CloudHealth Launch Liquid Biopsy Tests in China

NEW YORK (GenomeWeb) – Predicine announced today that its next-generation sequencing-based liquid biopsy diagnostics for lung cancer and prostate cancer are the first tests to launch in China under a co-promotion deal with Shanghai-based CloudHealth Genomics.

In April, the companies announced that they had signed a deal under which CloudHealth will provide clinical genetic testing infrastructure and sequencing capacity in China for Predicine's PrediSeq cell-free DNA NGS cancer diagnostics. 

According to Predicine, its PrediSeq-Lung and PrediSeq-Prostate liquid biopsy tests are the first covered under the partnership, with additional tests for major cancer types planned to launch in China later this year.